Cubist (CBST) Releases Positive Data on Two Phase 2 Studies of its Antibiotic Pipeline Candidates
Tweet Send to a Friend
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
